<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742050</url>
  </required_header>
  <id_info>
    <org_study_id>18SM4531</org_study_id>
    <nct_id>NCT03742050</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina</brief_title>
  <acronym>ORBITA-2</acronym>
  <official_title>A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basildon and Thurrock Hospitals NHS FoundationTrust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of
      coronary angioplasty versus placebo procedure on symptoms of stable angina without background
      anti-anginal therapy. Follow-up will be at 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in angina symptom score between groups</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in treadmill exercise time</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina severity as assessed by Canadian Cardiovascular Society class</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical limitation, angina stability, quality of life, angina frequency, freedom from angina as assessed with the Seattle Angina Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed with the EQ-5D-5L questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dobutamine stress echocardiography score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for anti-anginal medication introduction and up-titration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission for acute coronary syndrome or unscheduled coronary angiography</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from angina on symptom score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention with drug-eluting stents and modern techniques</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation</description>
    <arm_group_label>Percutaneous coronary intervention</arm_group_label>
    <arm_group_label>Placebo percutaneous coronary intervention</arm_group_label>
    <other_name>Coronary angioplasty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ORBITA-2 will enrol patients who meet all 3 of the following criteria:

          1. Angina or angina-equivalent symptoms

          2. Anatomical evidence of significant coronary stenosis in at least one vessel, either:
             a. Invasive diagnostic coronary angiogram indicating ≥ 70% stenosis b. CT coronary
             angiography indicating ≥ 90% stenosis

          3. Evidence of ischaemia, arising from at least one of the following options:

               1. Positive dobutamine stress echocardiography

               2. Positive cardiac MRI perfusion scan

               3. Positive nuclear medicine myocardial perfusion scan

               4. Invasive pressure wire assessment suggestive of ischaemia, as judged by the
                  interventional cardiologist, at the time of diagnostic angiogram or research
                  angiogram

        Exclusion Criteria:

          1. Age younger than 18

          2. Age older than 85

          3. Recent acute coronary event

          4. Previous coronary artery bypass graft surgery

          5. Significant left main stem coronary disease

          6. Chronic total occlusion in the target vessel

          7. Contraindication to percutaneous coronary intervention or drug-eluting stent
             implantation

          8. Contraindication to antiplatelet therapy

          9. Severe valvular disease

         10. Severe LV systolic impairment

         11. Severe respiratory disease

         12. Life expectancy less than 2 years, pregnancy, unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrel Francis, MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Nowbar</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasha Al-Lamee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rasha Al-Lamee, MRCP</last_name>
    <phone>020 7594 5735</phone>
    <email>rasha.al-lamee@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Nowbar, MRCP</last_name>
    <phone>020 7594 5735</phone>
    <email>alexandra.nowbar@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Basildon and Thurrock Hospitals NHS Foundation Trust</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Keeble, MD</last_name>
      <email>thomas.keeble@btuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH77DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter O'Kane</last_name>
      <email>peter.o'kane@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wycombe Hospital</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Petraco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasha K Al-Lamee, MRCP</last_name>
      <phone>07517551868</phone>
      <email>rasha.al-lamee@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra N Nowbar, MRCP</last_name>
      <phone>02075945735</phone>
      <email>alexandra.nowbar@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Rasha K Al-Lamee, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire NHS Foundation Trust</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Ruparelia, MRCP</last_name>
      <email>neil.ruparelia@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harefield Hospital</name>
      <address>
        <city>Uxbridge</city>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vas Panoulas</last_name>
      <email>V.Panoulas@rbht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable Angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

